Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ) has provided an update.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd., a Hong Kong-listed PRC pharmaceutical group, has released its unaudited financial results for the first quarter of 2026, prepared under Chinese accounting standards. The company’s board and senior management have formally attested to the truthfulness, accuracy and completeness of the disclosed information, underscoring a focus on regulatory compliance and transparency for investors.
The board confirmed that all directors attended the April 29, 2026 meeting at which the first-quarter report was considered and approved, signalling active governance oversight. The disclosure, made in line with Hong Kong securities regulations, serves primarily as a compliance and governance update rather than a detailed performance snapshot, but reiterates management’s legal responsibility for the integrity of the financial data.
The most recent analyst rating on (HK:9989) stock is a Sell with a HK$4.31 price target. To see the full list of analyst forecasts on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H stock, see the HK:9989 Stock Forecast page.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a Mainland China-based pharmaceutical company listed in Hong Kong, operating as a joint stock company with limited liability. The group is engaged in the development and production of pharmaceutical products and reports its financial results under PRC Accounting Standards and Accounting Regulations for Business Enterprises.
Average Trading Volume: 633,254
Technical Sentiment Signal: Sell
Current Market Cap: HK$16.62B
Learn more about 9989 stock on TipRanks’ Stock Analysis page.